NCT01631305

Brief Summary

The purpose of this study is to determine whether levothyroxine is effective and safe in the treatment of children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 29, 2012

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

March 5, 2014

Status Verified

March 1, 2014

Enrollment Period

1.9 years

First QC Date

June 26, 2012

Last Update Submit

March 4, 2014

Conditions

Keywords

Euthyroid Sick SyndromesThyroxineIntensive care

Outcome Measures

Primary Outcomes (1)

  • All cause mortality

    participants will be followed for the duration of hospital stay, an expected average of 3 weeks

Secondary Outcomes (4)

  • Length of time in intensive care

    participants will be followed for the duration of hospital stay, an expected average of 2 weeks

  • Ventilation days

    participants will be followed for the duration of hospital stay, an expected average of 2 weeks

  • Use of vasopressors

    participants will be followed for the duration of hospital stay, an expected average of 3 weeks

  • Thyroid hormones levels

    participants will be followed for the duration of hospital stay, an expected average of 3 weeks

Study Arms (2)

Levothyroxine

EXPERIMENTAL

3 mcg/kg/day

Drug: Levothyroxine

Control

PLACEBO COMPARATOR

Calcium magnesia.

Other: Calcium magnesia

Interventions

3 mcg/kg/day

Also known as: Brand: Eutirox.
Levothyroxine

Placebo.

Control

Eligibility Criteria

Age1 Month - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • All children aged 1 month to 17 years.
  • Admitted to pediatric intensive care unit.
  • TSH and thyroid hormones below age specific levels.

You may not qualify if:

  • Known thyroid condition.
  • Brain death.
  • Gut conditions that contraindicate oral route.
  • Readmissions to intensive care unit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sinaloa Pediatric Hospital

Culiacán, Sinaloa, 80200, Mexico

Location

Related Links

MeSH Terms

Conditions

Euthyroid Sick Syndromes

Interventions

Thyroxine

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Thyroid HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsAmino Acids, AromaticAmino Acids, CyclicAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Jesus J Martinez, MD

    Sinaloa Pediatric Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

June 26, 2012

First Posted

June 29, 2012

Study Start

January 1, 2012

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

March 5, 2014

Record last verified: 2014-03

Locations